Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...
MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...
GlobalData on MSN1d
MacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
ROCKVILLE, MD, USA I March 20, 2025 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study; Fast Track Designation granted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback